Discover a study that highlights dupilumab’s consistent efficacy in eosinophilic oesophagitis, even among patients with ...

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Dupilumab (Dupixent; Sanofi/Regeneron) has been approved to treat moderate to severe AD in children aged 6 months and older as well as in children who have asthma and eosinophilic esophagitis.

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Dupilumab use in asthma linked to higher lymphoma risk, especially T/NK cell types, though overall mortality was lower, new ...

Dupilumab (Dupixent), a medicine that you get as a shot, is the first new treatment for CSU in the U.S. in over a decade. It’s already used to treat different inflammation conditions in the U.S ...

DC-15442 is a potent small molecule STAT6 inhibitor, which is not a degrader or prodrug, being advanced as a safe dupilumab-in-a-pill alternative for patients BOSTON, June 10, 2025 /PRNewswire ...

Dupilumab Development ProgramDupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, ...

The dupilumab cohort had an increased risk for psoriasis (HR 1.58, 95% CI 1.25-1.99), although the risk for psoriatic arthritis (PsA) was not significant (HR 1.97, 95% CI 0.75-5.18).